OpenURL Connection Search

Select item for more details and to access through your institution.

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3<sup>rd</sup> Line Cetuximab and Irinotecan.
Published in:
PLoS ONE, 2014, v. 9, n. 6, p. 1, doi. 10.1371/journal.pone.0099886
By:
- Schou, Jakob V.;
- Rossi, Simona;
- Jensen, Benny V.;
- Nielsen, Dorte L.;
- Pfeiffer, Per;
- Høgdall, Estrid;
- Yilmaz, Mette;
- Tejpar, Sabine;
- Delorenzi, Mauro;
- Kruhøffer, Mogens;
- Johansen, Julia S.
Publication type:
Article
Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer.
Published in:
International Journal of Cancer, 2023, v. 152, n. 10, p. 2145, doi. 10.1002/ijc.34420
By:
- Eefsen, Rikke Løvendahl;
- Larsen, Jim S.;
- Klarskov, Louise L.;
- Altaf, Rahim;
- Høgdall, Estrid;
- Ingeholm, Peter;
- Lykke, Jakob;
- Nielsen, Dorte L.;
- Pfeiffer, Per;
- Poulsen, Laurids Ø.;
- Qvortrup, Camilla;
- Schou, Jakob V.;
- Mau‐Sørensen, Morten;
- Østerlind, Kell;
- Jensen, Benny V.
Publication type:
Article
Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.
Published in:
2017
By:
- Larsen, Finn Ole;
- Markussen, Alice;
- Jensen, Benny V;
- Fromm, Anne L;
- Vistisen, Kirsten K;
- Parner, Vibeke K;
- Linnemann, Dorte;
- Hansen, Rasmus H;
- Johannesen, Helle H;
- Schou, Jakob V
Publication type:
journal article
Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
Published in:
International Journal of Cancer, 2021, v. 148, n. 10, p. 2542, doi. 10.1002/ijc.33448
By:
- Jensen, Benny Vittrup;
- Schou, Jakob V.;
- Yilmaz, Mette;
- Johannesen, Helle H.;
- Skougaard, Kristin;
- Linnemann, Dorte;
- Hogdall, Estrid V.;
- Larsen, Finn O.;
- Johansen, Julia S.;
- Pfeiffer, Per;
- Nielsen, Dorte L.
Publication type:
Article
Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases.
Published in:
Molecular & Clinical Oncology, 2020, v. 13, n. 6, p. N.PAG, doi. 10.3892/mco.2020.2147
By:
- Boysen, Anders K.;
- Schou, Jakob V.;
- Jensen, Benny V.;
- Nielsen, Dorte;
- Sørensen, Brita S.;
- Johansen, Julia S.;
- Spindler, Karen-Lise G.
Publication type:
Article

Found: 5

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3<sup>rd</sup> Line Cetuximab and Irinotecan.

Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer.

Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.

Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.

Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases.